ライフサイエンスコーパス: sclerose

1 tall cell/columnar cell (89.5%) and diffuse sclerosing (10.5%) variants.

2 We reported on two patients with sclerosing adenosis assessed with mammography, ultrasoun

3 Sclerosing adenosis does not have distinctive radiologic

4 Sclerosing adenosis is a benign, usually asymptomatic lo

5 gn lesions, such as: granulomatous mastitis, sclerosing adenosis, chronic inflammation, fat necrosis,

6 The sclerosing agent was also present in the main portal vei

7 endobronchial valve, endobronchial coil, or sclerosing agents), the mean differences compared with t

8 ermeabilisation of the endothelium caused by sclerosing agents.

9 of visceralized parietal epithelial cells in sclerosing and collapsing lesions in a kidney biopsy fro

10 gioma responded to sildenafil after repeated sclerosing and drainage procedures failed to achieve rem

11 In contrast, diffuse sclerosing and tall cell/columnar variants are associate

12 Germline WTX mutations cause an X-linked sclerosing bone dysplasia but do not appear to predispos

13 Sclerosing cases were associated with an insidious onset

14 primary biliary cirrhosis (16%), and primary sclerosing cholangitis (13%) with an odds ratio of 2.3,

15 ancies (46.4%) and 114 patients with primary sclerosing cholangitis (62.3%).

16 Primarily indications for ERC were sclerosing cholangitis (75%) and malignant stenosis (9.5

17 1.34-2.74), and lower likelihood of primary sclerosing cholangitis (adjusted odds ratio 0.38; 95% CI

18 in autoimmune hepatitis (AIH) and autoimmune sclerosing cholangitis (AISC) either through inability o

19 ary sclerosing cholangitis (PSC), autoimmune sclerosing cholangitis (ASC), and autoimmune hepatitis (

20 cholangitis (IAC), also called IgG4-related sclerosing cholangitis (IRSC), to the spectrum of chroni

21 ancreatitis (n = 34) from those with primary sclerosing cholangitis (n = 17) and CA (n = 17).

22 Strictures in patients with primary sclerosing cholangitis (n = 86) were analyzed separately

23 imary biliary cirrhosis (PBC, n=76), primary sclerosing cholangitis (n=81), hepatitis C virus (HCV) (

24 Neonatal ichthyosis and sclerosing cholangitis (NISCH) syndrome is a liver disea

25 all P = .003), as well as absence of primary sclerosing cholangitis (P = .011).

26 tis C virus (P = 0.01, HR = 1.6) and primary sclerosing cholangitis (P = 0.03, HR = 2.9).

27 ns for celiac disease (P = 0.22) and primary sclerosing cholangitis (P = 0.078) were not associated w

28 The prevalence of primary sclerosing cholangitis (PSC) among patients with inflamm

29 primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) and assessed both vertebral

30 sis occurs during the progression of primary sclerosing cholangitis (PSC) and is characterized by acc

31 Primary sclerosing cholangitis (PSC) and primary biliary cholang

32 Patients with primary sclerosing cholangitis (PSC) are at an increased risk fo

33 Patients with primary sclerosing cholangitis (PSC) are at increased risk for d

34 Primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) are infrequent autoimmune c

35 tologic scoring systems specific for primary sclerosing cholangitis (PSC) are not validated.

36 primary biliary cirrhosis (PBC), and primary sclerosing cholangitis (PSC) are scarce.

37 Primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) are uncommon liver diseases

38 s serum liver tests in patients with primary sclerosing cholangitis (PSC) but does not improve surviv

39 eased donor livers for patients with primary sclerosing cholangitis (PSC) due to the weighting of the

40 proximately 60%-80% of patients with primary sclerosing cholangitis (PSC) have concurrent ulcerative

41 developing varices in patients with primary sclerosing cholangitis (PSC) have not been well studied

42 ulation-level data on the effects of primary sclerosing cholangitis (PSC) in patients with inflammato

43 Primary sclerosing cholangitis (PSC) is a cholestatic liver dise

44 Primary sclerosing cholangitis (PSC) is a chronic bile duct dise

45 Primary sclerosing cholangitis (PSC) is a chronic cholestatic di

46 Primary sclerosing cholangitis (PSC) is a chronic cholestatic li

47 Primary sclerosing cholangitis (PSC) is a chronic cholestatic li

48 Primary sclerosing cholangitis (PSC) is a chronic cholestatic li

49 Primary sclerosing cholangitis (PSC) is a chronic fibroinflammat

50 Primary sclerosing cholangitis (PSC) is a chronic inflammatory c

51 Primary sclerosing cholangitis (PSC) is a chronic inflammatory l

52 Primary sclerosing cholangitis (PSC) is a chronic, fibroinflamma

53 Primary sclerosing cholangitis (PSC) is a chronic, idiopathic, f

54 Primary sclerosing cholangitis (PSC) is a heterogeneous and prog

55 Primary sclerosing cholangitis (PSC) is a rare but important liv

56 Primary sclerosing cholangitis (PSC) is a rare progressive disor

57 Primary sclerosing cholangitis (PSC) is a rare, but serious, cho

58 Because primary sclerosing cholangitis (PSC) is a risk factor for CCA, s

59 Primary sclerosing cholangitis (PSC) is a severe liver disease o

60 Primary sclerosing cholangitis (PSC) is an idiopathic, progressi

61 Primary sclerosing cholangitis (PSC) is an incurable cholangiopa

62 BACKGROUND & AIMS: Primary sclerosing cholangitis (PSC) is an orphan hepatobiliary

63 Patients with primary sclerosing cholangitis (PSC) may be at higher risk of ma

64 time may predict colectomy, whereas primary sclerosing cholangitis (PSC) may be protective.

65 isk of biliary tract cancer (BTC) in primary sclerosing cholangitis (PSC) may exceed 20%, and BTC is

66 Pathogenesis of primary sclerosing cholangitis (PSC) may involve impaired bile a

67 features of patients with small-duct primary sclerosing cholangitis (PSC) occurring with and without

68 stricture formation in patients with primary sclerosing cholangitis (PSC) or after liver transplantat

69 ed specifically in cholangiocytes of primary sclerosing cholangitis (PSC) patients and in mice subjec

70 Primary sclerosing cholangitis (PSC) patients pose a particularl

71 Primary sclerosing cholangitis (PSC) patients suffer from comorb

72 o summarize publications on juvenile primary sclerosing cholangitis (PSC) published over the past 5 y

73 The pathogenesis of primary sclerosing cholangitis (PSC) remains poorly understood.

74 Primary sclerosing cholangitis (PSC) represents a major unmet me

75 T cells from patients with primary sclerosing cholangitis (PSC) show a prominent IL-17 resp

76 T cells from patients with primary sclerosing cholangitis (PSC) show a prominent interleuki

77 For patients with primary sclerosing cholangitis (PSC) suffering from bacterial ch

78 Primary sclerosing cholangitis (PSC) was present in 31/126 CCA p

79 The pathogenesis of primary sclerosing cholangitis (PSC), a progressive biliary trac

80 Primary sclerosing cholangitis (PSC), age, history of cholecyste

81 ects, including 28 with PBC, 13 with primary sclerosing cholangitis (PSC), and 18 healthy controls.

82 ses primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), and alcoholic liver diseas

83 plantation or death in patients with primary sclerosing cholangitis (PSC), and to develop and validat

84 rimary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), are frequently associated

85 Several conditions, such as primary sclerosing cholangitis (PSC), are risk factors.

86 atic tissue from patients with AP or primary sclerosing cholangitis (PSC), as well as from mice.

87 ogy and natural history of pediatric primary sclerosing cholangitis (PSC), autoimmune sclerosing chol

88 In primary sclerosing cholangitis (PSC), bile fluid is frequently c

89 bowel disease may be accompanied by primary sclerosing cholangitis (PSC), but seldom primary biliary

90 arly primary biliary cholangitis and primary sclerosing cholangitis (PSC), evolve over time with anat

91 Primary sclerosing cholangitis (PSC), first described in the mid

92 e been demonstrated in patients with primary sclerosing cholangitis (PSC), must be accompanied by fun

93 for detecting cholangiocarcinoma in primary sclerosing cholangitis (PSC), particularly when used seq

94 The influence of sex on primary sclerosing cholangitis (PSC), pre and post-liver transpl

95 primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC), results from an impairment

96 In primary sclerosing cholangitis (PSC), the focus of this review,

97 fibrosis in animal models and human primary sclerosing cholangitis (PSC).

98 ng disease activity and prognosis in primary sclerosing cholangitis (PSC).

99 which is increased in patients with primary sclerosing cholangitis (PSC).

100 iated biliary injury is a feature of primary sclerosing cholangitis (PSC).

101 e, other benign disease, tumour, and primary sclerosing cholangitis (PSC).

102 or management of adult patients with primary sclerosing cholangitis (PSC).

103 andard of reference for diagnosis of primary sclerosing cholangitis (PSC).

104 and disease course in patients with primary sclerosing cholangitis (PSC).

105 not been well studied in those with primary sclerosing cholangitis (PSC).

106 deoxycholic acid (UDCA) for treating primary sclerosing cholangitis (PSC).

107 primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC).

108 primary biliary cirrhosis (PBC), and primary sclerosing cholangitis (PSC).

109 nd predict outcomes in patients with primary sclerosing cholangitis (PSC).

110 e obtained from patients affected by primary sclerosing cholangitis (PSC).

111 rimary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC).

112 the serum and liver of patients with primary sclerosing cholangitis (PSC).

113 iocyte senescence has been linked to primary sclerosing cholangitis (PSC).

114 n of cholangiopathies, in particular primary sclerosing cholangitis (PSC).

115 s; however, no information exists in primary sclerosing cholangitis (PSC).

116 ated inflammatory diseases including primary sclerosing cholangitis (PSC).

117 reported in 9%-15% of patients with primary sclerosing cholangitis (PSC); it is not clear whether th

118 static diseases such as primary or secondary sclerosing cholangitis (PSC, SSC) and primary biliary ch

119 ignancy was highest in patients with primary sclerosing cholangitis (PSC; 22% at 10 years) or alcohol

120 ary biliary cirrhosis (PBC; n=3052), primary sclerosing cholangitis (PSC; n=3854), hepatitis C virus

121 reater primary dysfunction GF, while primary sclerosing cholangitis (PSC; P=0.0002) implied greater v

122 carcinoma (HCC) (SMR 38.4-18.8), and primary sclerosing cholangitis (SMR 11.0-4.2), and deterioration

123 imary biliary cholangitis [PBC], and primary sclerosing cholangitis [PSC]), we built a comprehensive

124 Primary biliary cirrhosis, primary sclerosing cholangitis and biliary atresia are thought t

125 nd pancreas is difficult to distinguish from sclerosing cholangitis and biliary/pancreatic malignanci

126 also detected in human patients with primary sclerosing cholangitis and hepatobiliary cholangiopathie

127 Primary sclerosing cholangitis and immunosuppressive use were no

128 1.9, P < .005) and in patients with primary sclerosing cholangitis and in severity were independentl

129 ular, the strong comorbidity between primary sclerosing cholangitis and inflammatory bowel disease is

130 AP in the bile ductular reactions of primary sclerosing cholangitis and primary biliary cirrhosis pat

131 immune-mediated diseases, including primary sclerosing cholangitis and primary biliary cirrhosis, bu

132 dylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis and ulcerative colitis to investi

133 lymphedema, protein loosing enteropathy, and sclerosing cholangitis and was diagnosed with lymphedema

134 en, with only 7 patients having a history of sclerosing cholangitis and/or inflammatory bowel disease

135 ncluding autoimmune hepatitis and autoimmune sclerosing cholangitis ASC).

136 sitive biliary strictures resembling primary sclerosing cholangitis but with increased serum immunogl

137 s liver fibrosis in a mouse model of primary sclerosing cholangitis by miR-200b down-regulation.

138 Differentiation of primary sclerosing cholangitis can be challenging because other

139 samples (15 CCAs and 20 nonmalignant primary sclerosing cholangitis controls), and the methylation st

140 arkers was validated (34 CCAs and 34 primary sclerosing cholangitis controls).

141 gram results, but the syndrome of autoimmune sclerosing cholangitis does not affect immediate prognos

142 in in Mdr2 knockout (KO) mice, which develop sclerosing cholangitis due to regurgitation of BA from l

143 ural history of large and small duct primary sclerosing cholangitis has been reviewed.

144 Patients with primary sclerosing cholangitis have a poor prognosis; progressio

145 antigen haplotype associations with primary sclerosing cholangitis have been investigated.

146 e gene polymorphisms associated with primary sclerosing cholangitis have been investigated.

147 Liver histology of sclerosing cholangitis improved, and extent of fibrosis

148 Primary sclerosing cholangitis in children can mimic autoimmune

149 id transporter (ASBT), blocks progression of sclerosing cholangitis in mdr2(-/-) mice.

150 1,4-dihydrocollidine (DDC) feeding to induce sclerosing cholangitis in wild-type (WT) and knockout (M

151 Symptoms of primary sclerosing cholangitis include fatigue, jaundice, prurit

152 Primary sclerosing cholangitis is a chronic cholestatic disease

153 Primary sclerosing cholangitis is a chronic cholestatic liver di

154 Primary sclerosing cholangitis is a chronic cholestatic liver di

155 Primary sclerosing cholangitis is a chronic immune-mediated live

156 Primary sclerosing cholangitis is a chronic, progressive cholang

157 Treatment of primary sclerosing cholangitis is confined to supportive measure

158 ate that the colitis associated with primary sclerosing cholangitis is pathophysiologically distinct

159 Primary sclerosing cholangitis is the classic hepatobiliary mani

160 The etiopathogenesis of primary sclerosing cholangitis is unknown.

161 The best-studied drug in primary sclerosing cholangitis is ursodeoxycholic acid, which, d

162 r activation in vitro and in vivo in primary sclerosing cholangitis liver specimens.

163 PBC livers, compared with normal and primary sclerosing cholangitis livers.

164 It is suggested that primary sclerosing cholangitis may have a bacterial cause.

165 Sclerosing cholangitis may recur after transplantation,

166 Primary sclerosing cholangitis mice and patients have increased

167 Abcb4(-/-); Mdr2(-/-)) knockout (KO) mice, a sclerosing cholangitis model.

168 human liver samples from control or primary sclerosing cholangitis patients were evaluated for MC ma

169 s been demonstrated in a subgroup of primary sclerosing cholangitis patients, which may indicate an o

170 ve CCA detection, particularly among primary sclerosing cholangitis patients.

171 hepatitis (HR, 1.35; P < 0.001), and primary sclerosing cholangitis pre-LT (compared with hepatitis C

172 bacteria in the etiopathogenesis of primary sclerosing cholangitis remains to be determined.

173 le modeling using RC, FISH, age, and primary sclerosing cholangitis status can be used to estimate th

174 , trisomy FISH, suspicious cytology, primary sclerosing cholangitis status, and age were associated w

175 tween inflammatory bowel disease and primary sclerosing cholangitis underscores the need to further u

176 Cirrhosis not related to primary sclerosing cholangitis was associated with both intrahep

177 Primary sclerosing cholangitis was more strongly associated with

178 d inflammatory bowel disease without primary sclerosing cholangitis was not associated with any CCA s

179 A paucity of research studies on primary sclerosing cholangitis was noted in this review and futu

180 Sclerosing cholangitis was the most important risk facto

181 For all recipients, female sex and primary sclerosing cholangitis were associated with improved sur

182 disease, and those with concomitant primary sclerosing cholangitis were at increased risk.

183 Patients suspected to have secondary sclerosing cholangitis were excluded.

184 ciated primary biliary cirrhosis and primary sclerosing cholangitis with genes encoding major histoco

185 itis with pancreatic pseudotumour, n = 7; e) Sclerosing cholangitis with hepatic pseudotumour, n = 3;

186 mples from patients with and without primary sclerosing cholangitis with higher levels of sensitivity

187 Sclerosing cholangitis with strong autoimmune features i

188 vs. 0.6%), hepatobiliary (including primary sclerosing cholangitis) (5.5% vs. 0.1%), pancreatic (1.7

189 s (or any duration, if they also had primary sclerosing cholangitis) and no history of advanced CRN (

190 rbonyl-1,4-dihydrocollidine (DDC; a model of sclerosing cholangitis) for 4 weeks.

191 4-dihydrocollidine (DDC) feeding (a model of sclerosing cholangitis) or bile duct ligation (BDL).

192 ther inflammatory disorders (such as primary sclerosing cholangitis), whereas it decreases when patie

193 ls with autoimmune diseases (18 with primary sclerosing cholangitis, 16 with autoimmune hepatitis, an

194 iver and bile duct injury in mouse models of sclerosing cholangitis, a disease so far lacking effecti

195 in CLDs (primary biliary cirrhosis, primary sclerosing cholangitis, alcoholic liver disease, and chr

196 ues were obtained from patients with primary sclerosing cholangitis, alcoholic liver disease, or nona

197 ic cholestasis, biliary atresia, and primary sclerosing cholangitis, and clinical trials of therapies

198 Patients with autoimmune hepatitis, primary sclerosing cholangitis, and primary biliary cirrhosis as

199 rent autoimmune hepatitis, recurrent primary sclerosing cholangitis, and recurrent primary biliary ci

200 CC, including parasitic infections, primary sclerosing cholangitis, biliary-duct cysts, hepatolithia

201 may play a role in biliary atresia, primary sclerosing cholangitis, cellular rejection, and primary

202 atment of primary biliary cirrhosis, primary sclerosing cholangitis, cholestasis of pregnancy, total

203 including primary biliary cirrhosis, primary sclerosing cholangitis, chronic hepatitis C, and postnec

204 ure research efforts should focus on primary sclerosing cholangitis, in addition to primary biliary c

205 sights have arisen from studies of secondary sclerosing cholangitis, in which a similar clinical prof

206 sociated with ulcerative colitis and primary sclerosing cholangitis, inflammatory diseases with a hig

207 s such as primary biliary cirrhosis, primary sclerosing cholangitis, intrahepatic cholestasis of preg

208 malignant PVT, after exclusion of those with sclerosing cholangitis, liver transplants, choledocholit

209 cy included concomitant diagnosis of primary sclerosing cholangitis, longstanding colitis (>10 years)

210 4 patients included autoimmune pancreatitis, sclerosing cholangitis, lymphoplasmacytic aortitis, sali

211 ing pancreatitis and cholangitis, n = 21; b) Sclerosing cholangitis, n = 9; c) Sclerosing pancreatiti

212 ectable or arising in the setting of primary sclerosing cholangitis, neoadjuvant chemoradiotherapy fo

213 in nonalcoholic fatty liver disease, primary sclerosing cholangitis, neonatal hemochromatosis, acute

214 st LT for primary biliary cirrhosis, primary sclerosing cholangitis, or alcoholic cirrhosis (group I)

215 Underlying primary sclerosing cholangitis, percutaneous biliary intubation,

216 for low-grade dysplasia, strictures, primary sclerosing cholangitis, post-inflammatory polyps, family

217 In liver tissues from patients with primary sclerosing cholangitis, primary biliary cholangitis, chr

218 er tissue samples from patients with primary sclerosing cholangitis, primary biliary cholangitis, hep

219 ease, non-alcoholic steatohepatitis, primary sclerosing cholangitis, total parenteral nutrition-assoc

220 emonstrated in biliary lithiasis and primary sclerosing cholangitis, two cholangiopathies regarded as

221 ic cholangitides, the most common is primary sclerosing cholangitis, which is associated with inflamm

222 icult, particularly in patients with primary sclerosing cholangitis, who are at risk of developing th

223 Primary sclerosing cholangitis-inflammatory bowel disease probab

224 amilial intrahepatic cholestasis and primary sclerosing cholangitis.

225 MC mediators may be therapeutic for primary sclerosing cholangitis.

226 response such as alcoholic liver disease or sclerosing cholangitis.

227 kocytes, and abrogates progression of murine sclerosing cholangitis.

228 t both primary biliary cirrhosis and primary sclerosing cholangitis.

229 ity of primary biliary cirrhosis and primary sclerosing cholangitis.

230 static entities, primary (PSC) and secondary sclerosing cholangitis.

231 n may be considered as potential therapy for sclerosing cholangitis.

232 ones, primary biliary cirrhosis, and primary sclerosing cholangitis.

233 ngitis and the steroid-nonresponsive primary sclerosing cholangitis.

234 from UC that is not associated with primary sclerosing cholangitis.

235 f 38.5% observed among patients with primary sclerosing cholangitis.

236 c disease, chronic pancreatitis, and primary sclerosing cholangitis.

237 n haplotypes are not associated with primary sclerosing cholangitis.

238 otein 2 knockout (Mdr2(-/-) ) mouse model of sclerosing cholangitis.

239 itis, primary biliary cirrhosis, and primary sclerosing cholangitis.

240 nancy, primary biliary cirrhosis and primary sclerosing cholangitis.

241 on does not appear to directly cause primary sclerosing cholangitis.

242 ve been detected in liver tissues in primary sclerosing cholangitis.

243 ancy, primary biliary cirrhosis, and primary sclerosing cholangitis.

244 established long-term treatment for primary sclerosing cholangitis.

245 n age was 49, and 88% had underlying primary sclerosing cholangitis.

246 ng human cholangiopathies, including primary sclerosing cholangitis.

247 e, respectively) and subjected to a model of sclerosing cholangitis.

248 There were 7 patients with primary sclerosing cholangitis.

249 effects to severe disorders, such as primary sclerosing cholangitis.

250 ous complications in patients with secondary sclerosing cholangitis.

251 f ERC, especially in patients with secondary sclerosing cholangitis.

252 iary tuberculosis with features of secondary sclerosing cholangitis.

253 tal antimicrobials were those with secondary sclerosing cholangitis.

254 Still rarer is its presentation as sclerosing cholangitis.

255 ociation studies as risk factors for primary sclerosing cholangitis.

256 e most studied medical treatment for primary sclerosing cholangitis; pilot studies suggest a possible

257 do not confer any susceptibility to primary sclerosing cholangitis; the role of intercellular adhesi

258 /=1 per 4 mm(2)) and 37% with nonspecific or sclerosing chronic sialadenitis (NS/SCS).

259 Melorheostosis is a rare sclerosing dysostosis characterized by asymmetric exuber

260 te to the pathogenesis of podocyte injury in sclerosing glomerulopathies such as focal segmental glom

261 and kidney biopsy analysis showed a nodular sclerosing GN with extensive focal global glomeruloscler

262 ical examination diagnosed Hodgkin's nodular sclerosing histological subtype disease has been establi

263 Medial canthal BCCs, morpheaform, or sclerosing histology were not more common in the recurre

264 With more severe immunosuppression, nodular sclerosing HL becomes infrequent, explaining the higher

265 p24.1 amplification is restricted to nodular sclerosing HL, the cHL subtype most closely related to M

266 Nodular sclerosing Hodgkin lymphoma (NSHL) is a distinct, highly

267 , in fact, closely resemble those of nodular sclerosing Hodgkin lymphoma (NSHL).

268 lymphoma that is closely related to nodular sclerosing Hodgkin's lymphoma.

269 yndrome caused by stage 2A, grade I, nodular sclerosing Hodgkin's lymphoma.

270 onfidence interval (CI) 1.1-1.3] and diffuse sclerosing HR 1.3; 95% CI 1.0-1.7]}.

271 NT FINDINGS: Emerging evidence suggests that sclerosing idiopathic orbital inflammation can be an IgG

272 Sclerosing idiopathic orbital inflammation is a rare dis

273 Sclerosing idiopathic orbital inflammation is a rare, di

274 arge, controlled study comparing the various sclerosing idiopathic orbital inflammation treatments ar

275 patients and immunoglobulin (Ig) G4-related sclerosing inflammation in 7 patients.

276 (P = 0.002, Fisher exact test), but not with sclerosing inflammation present in 28% (13 of 46).

277 [52 of 179] at DM P = .35), but more radial sclerosing lesions (8.3% [95% confidence interval {CI}:

278 tural distortions were biopsied, more radial sclerosing lesions were identified, and more discordance

279 olycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy (PLOSL).

280 Sclerosing lymphoplasmacytic inflammation at almost any

281 imens of IgA nephropathy and one specimen of sclerosing membranoproliferative GN, showed bright (2-3+

282 Sclerosing mesenteritis (SM) is sometimes used as an umb

283 rosis, reactive nodular fibrous pseudotumor, sclerosing mesenteritis, and membranous glomerulonephrit

284 n = 9; c) Sclerosing pancreatitis, n = 4; d) Sclerosing pancreatitis and cholangitis with pancreatic

285 Where discernible, disease was a) Sclerosing pancreatitis and cholangitis, n = 21; b) Scle

286 angitis with hepatic pseudotumour, n = 3; f) Sclerosing pancreatitis with pancreatic pseudotumour, n

287 n divided into subtypes 1 (lymphoplasmacytic sclerosing pancreatitis) and 2 (idiopathic duct centric

288 n = 21; b) Sclerosing cholangitis, n = 9; c) Sclerosing pancreatitis, n = 4; d) Sclerosing pancreatit

289 Subacute sclerosing panencephalitis (SSPE) is a fatal complicatio

290 In some cases, MeV persistence and subacute sclerosing panencephalitis (SSPE) occur even in the face

291 virus infection of the brain causes subacute sclerosing panencephalitis (SSPE), a progressive, relent

292 tal neurodegenerative complication, subacute sclerosing panencephalitis (SSPE), occurs during persist

293 later, children are presenting with subacute sclerosing panencephalitis (SSPE).

294 he presence of small lesions indicative of a sclerosing process were detected, which were undetectabl

295 ed in 70% HG was superior to 75% HG alone in sclerosing reticular veins, with no statistical differen

296 metaphyseal dysplasia (FMD) is a progressive sclerosing skeletal dysplasia affecting the long bones a

297 Sclerosing stromal tumor (SST) of the ovary is a rare ty

298 pillary tumors compared with the more common sclerosing tumors.

299 utcome compared with the more common nodular-sclerosing type.

300 The most common of these include the diffuse sclerosing variant, tall cell variant, and insular thyro